- Home
- PTGX vs SLNO Comparison
PTGX vs SLNO Comparison
Compare PTGX & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTGX
- SLNO
- Stock Information
- Founded
- PTGX 2006
- SLNO 1999
- Country
- PTGX United States
- SLNO United States
- Employees
- PTGX 130
- SLNO N/A
- Industry
- PTGX Biotechnology: Pharmaceutical Preparations
- SLNO Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- PTGX Health Care
- SLNO Health Care
- Exchange
- PTGX Nasdaq
- SLNO Nasdaq
- Market Cap
- PTGX 5.0B
- SLNO 3.7B
- IPO Year
- PTGX 2016
- SLNO 2014
- Fundamental
- Price
- PTGX $79.54
- SLNO $46.98
- Analyst Decision
- PTGX Strong Buy
- SLNO Strong Buy
- Analyst Count
- PTGX 9
- SLNO 9
- Target Price
- PTGX $86.22
- SLNO $114.89
- AVG Volume (30 Days)
- PTGX 1.3M
- SLNO 2.2M
- Earning Date
- PTGX 11-06-2025
- SLNO 11-04-2025
- Dividend Yield
- PTGX N/A
- SLNO N/A
- EPS Growth
- PTGX N/A
- SLNO N/A
- EPS
- PTGX 0.72
- SLNO N/A
- Revenue
- PTGX $209,217,000.00
- SLNO $98,675,000.00
- Revenue This Year
- PTGX N/A
- SLNO N/A
- Revenue Next Year
- PTGX $140.23
- SLNO $181.30
- P/E Ratio
- PTGX $110.77
- SLNO N/A
- Revenue Growth
- PTGX N/A
- SLNO N/A
- 52 Week Low
- PTGX $33.31
- SLNO $41.50
- 52 Week High
- PTGX $93.25
- SLNO $90.32
- Technical
- Relative Strength Index (RSI)
- PTGX 62.21
- SLNO 31.94
- Support Level
- PTGX $75.44
- SLNO $66.12
- Resistance Level
- PTGX $80.43
- SLNO $69.99
- Average True Range (ATR)
- PTGX 2.61
- SLNO 3.71
- MACD
- PTGX -0.23
- SLNO -2.47
- Stochastic Oscillator
- PTGX 89.38
- SLNO 18.57
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.